AU2002361990A1 - Substituted imidazolidines, method for the production thereof, use thereof as a drug or for diagnosis, and drug containing substituted imidazolidines - Google Patents
Substituted imidazolidines, method for the production thereof, use thereof as a drug or for diagnosis, and drug containing substituted imidazolidines Download PDFInfo
- Publication number
- AU2002361990A1 AU2002361990A1 AU2002361990A AU2002361990A AU2002361990A1 AU 2002361990 A1 AU2002361990 A1 AU 2002361990A1 AU 2002361990 A AU2002361990 A AU 2002361990A AU 2002361990 A AU2002361990 A AU 2002361990A AU 2002361990 A1 AU2002361990 A1 AU 2002361990A1
- Authority
- AU
- Australia
- Prior art keywords
- ylidene
- dichlorophenyl
- compound
- medicament
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims description 43
- 238000004519 manufacturing process Methods 0.000 title description 14
- 238000000034 method Methods 0.000 title description 8
- 150000002461 imidazolidines Chemical class 0.000 title description 7
- 229940079593 drug Drugs 0.000 title description 5
- 238000003745 diagnosis Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 78
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 125000001153 fluoro group Chemical group F* 0.000 claims description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 16
- 238000011321 prophylaxis Methods 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 229910052794 bromium Inorganic materials 0.000 claims description 12
- 229910052740 iodine Inorganic materials 0.000 claims description 12
- -1 (C 1 -C4)-alkenyl Chemical group 0.000 claims description 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 230000000241 respiratory effect Effects 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims description 6
- 208000023504 respiratory system disease Diseases 0.000 claims description 6
- 201000002859 sleep apnea Diseases 0.000 claims description 6
- AJYDVVQTXOEESN-ACMTZBLWSA-N (3as,7as)-n-(2,6-dichlorophenyl)-3a,4,5,6,7,7a-hexahydro-1h-benzimidazol-2-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.ClC1=CC=CC(Cl)=C1N=C1N[C@H]2CCCC[C@@H]2N1 AJYDVVQTXOEESN-ACMTZBLWSA-N 0.000 claims description 5
- HSMHWAGYMUFUCH-QNTKWALQSA-N (4s,5s)-n-(2,6-dichlorophenyl)-4,5-di(propan-2-yl)-4,5-dihydro-1h-imidazol-2-amine;hydrochloride Chemical compound Cl.CC(C)[C@H]1[C@H](C(C)C)NC(NC=2C(=CC=CC=2Cl)Cl)=N1 HSMHWAGYMUFUCH-QNTKWALQSA-N 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- 206010041235 Snoring Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- YCNIBOIOWCTRCL-UHFFFAOYSA-N azane;2,2,2-trifluoroacetic acid Chemical class [NH4+].[O-]C(=O)C(F)(F)F YCNIBOIOWCTRCL-UHFFFAOYSA-N 0.000 claims description 5
- AJYDVVQTXOEESN-NDXYWBNTSA-N (3ar,7ar)-n-(2,6-dichlorophenyl)-3a,4,5,6,7,7a-hexahydro-1h-benzimidazol-2-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.ClC1=CC=CC(Cl)=C1N=C1N[C@@H]2CCCC[C@H]2N1 AJYDVVQTXOEESN-NDXYWBNTSA-N 0.000 claims description 4
- UKCGZUYIISCPPJ-QNBGGDODSA-N (3ar,7ar)-n-(2-phenoxyphenyl)-3a,4,5,6,7,7a-hexahydro-1h-benzimidazol-2-amine;hydrochloride Chemical compound Cl.N([C@@H]1CCCC[C@H]1N1)=C1NC1=CC=CC=C1OC1=CC=CC=C1 UKCGZUYIISCPPJ-QNBGGDODSA-N 0.000 claims description 4
- KOAAJGXPQKOVKY-ACMTZBLWSA-N (4s,5s)-n-(2,6-dichlorophenyl)-4,5-diethyl-4,5-dihydro-1h-imidazol-2-amine;hydrochloride Chemical compound Cl.CC[C@H]1[C@H](CC)NC(NC=2C(=CC=CC=2Cl)Cl)=N1 KOAAJGXPQKOVKY-ACMTZBLWSA-N 0.000 claims description 4
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- LWOGOQREXQIPDS-UHFFFAOYSA-N n-(2,6-dichlorophenyl)-4,5-dimethyl-4,5-dihydro-1h-imidazol-2-amine;nitric acid Chemical compound O[N+]([O-])=O.N1C(C)C(C)NC1=NC1=C(Cl)C=CC=C1Cl LWOGOQREXQIPDS-UHFFFAOYSA-N 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 230000035939 shock Effects 0.000 claims description 4
- NETDSGHQEHKVOX-QNTKWALQSA-N (4s,5s)-4,5-dicyclopropyl-n-(2,6-dichlorophenyl)-4,5-dihydro-1h-imidazol-2-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.ClC1=CC=CC(Cl)=C1NC(N[C@H]1C2CC2)=N[C@H]1C1CC1 NETDSGHQEHKVOX-QNTKWALQSA-N 0.000 claims description 3
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 244000078703 ectoparasite Species 0.000 claims description 3
- 238000011477 surgical intervention Methods 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 3
- QBJQFFGENHPKLI-DHTOPLTISA-N (3ar,6ar)-n-(2,6-dichlorophenyl)-1,3a,4,5,6,6a-hexahydrocyclopenta[d]imidazol-2-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.ClC1=CC=CC(Cl)=C1N=C1N[C@@H]2CCC[C@H]2N1 QBJQFFGENHPKLI-DHTOPLTISA-N 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000030090 Acute Disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000003871 intestinal function Effects 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- 239000000203 mixture Substances 0.000 description 26
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000003112 inhibitor Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 206010021143 Hypoxia Diseases 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 108091006649 SLC9A3 Proteins 0.000 description 7
- 102100030375 Sodium/hydrogen exchanger 3 Human genes 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 6
- SUCGVQHNGIQXGD-UHFFFAOYSA-N 1,3-dichloro-2-isothiocyanatobenzene Chemical compound ClC1=CC=CC(Cl)=C1N=C=S SUCGVQHNGIQXGD-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007954 hypoxia Effects 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 description 3
- YEZPUVHMNQGLLE-NDXYWBNTSA-N (3ar,7ar)-n-[2-chloro-6-(trifluoromethyl)phenyl]-3a,4,5,6,7,7a-hexahydro-1h-benzimidazol-2-amine;hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(Cl)=C1NC(N1)=N[C@H]2[C@H]1CCCC2 YEZPUVHMNQGLLE-NDXYWBNTSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020591 Hypercapnia Diseases 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 108091006650 SLC9A2 Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 102100030382 Sodium/hydrogen exchanger 2 Human genes 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960002896 clonidine Drugs 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000000055 hyoplipidemic effect Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 150000002540 isothiocyanates Chemical class 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- CSRPLQNKSUMCOX-HZPDHXFCSA-N 1-[(1r,2r)-2-aminocyclohexyl]-3-(2-phenoxyphenyl)thiourea Chemical compound N[C@@H]1CCCC[C@H]1NC(=S)NC1=CC=CC=C1OC1=CC=CC=C1 CSRPLQNKSUMCOX-HZPDHXFCSA-N 0.000 description 2
- FJWHYKAVKBPKGC-GHMZBOCLSA-N 1-[(1r,2r)-2-aminocyclohexyl]-3-[2-chloro-6-(trifluoromethyl)phenyl]urea Chemical compound N[C@@H]1CCCC[C@H]1NC(=O)NC1=C(Cl)C=CC=C1C(F)(F)F FJWHYKAVKBPKGC-GHMZBOCLSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- HERQJOQHRKNLIP-UHFFFAOYSA-N 1-isothiocyanato-2-phenoxybenzene Chemical compound S=C=NC1=CC=CC=C1OC1=CC=CC=C1 HERQJOQHRKNLIP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010061217 Infestation Diseases 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 206010040978 Sleep apnoeas Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000034972 Sudden Infant Death Diseases 0.000 description 2
- 206010042440 Sudden infant death syndrome Diseases 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000036523 atherogenesis Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 150000001723 carbon free-radicals Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- SSJXIUAHEKJCMH-OLQVQODUSA-N (1s,2r)-cyclohexane-1,2-diamine Chemical compound N[C@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-OLQVQODUSA-N 0.000 description 1
- SSJXIUAHEKJCMH-WDSKDSINSA-N (1s,2s)-cyclohexane-1,2-diamine Chemical compound N[C@H]1CCCC[C@@H]1N SSJXIUAHEKJCMH-WDSKDSINSA-N 0.000 description 1
- BTECYKNYXNTZIT-NXEZZACHSA-N (3ar,6ar)-n-(2,6-dichlorophenyl)-1,3a,4,5,6,6a-hexahydrocyclopenta[d]imidazol-2-amine Chemical compound ClC1=CC=CC(Cl)=C1NC(N1)=N[C@H]2[C@H]1CCC2 BTECYKNYXNTZIT-NXEZZACHSA-N 0.000 description 1
- YPKFCLPJFWWBJG-GHMZBOCLSA-N (3ar,7ar)-n-(2,6-dichlorophenyl)-3a,4,5,6,7,7a-hexahydro-1h-benzimidazol-2-amine Chemical compound ClC1=CC=CC(Cl)=C1NC(N1)=N[C@H]2[C@H]1CCCC2 YPKFCLPJFWWBJG-GHMZBOCLSA-N 0.000 description 1
- YFCBKASXGFZJSY-STQMWFEESA-N (4s,5s)-4,5-dicyclopropyl-n-(2,6-dichlorophenyl)-4,5-dihydro-1h-imidazol-2-amine Chemical compound ClC1=CC=CC(Cl)=C1NC(N[C@H]1C2CC2)=N[C@H]1C1CC1 YFCBKASXGFZJSY-STQMWFEESA-N 0.000 description 1
- IVWTXAFZRSKBNW-ZIAGYGMSSA-N (4s,5s)-4,5-ditert-butyl-n-(2,6-dichlorophenyl)-4,5-dihydro-1h-imidazol-2-amine Chemical compound CC(C)(C)[C@H]1[C@H](C(C)(C)C)NC(NC=2C(=CC=CC=2Cl)Cl)=N1 IVWTXAFZRSKBNW-ZIAGYGMSSA-N 0.000 description 1
- OCBLPDGFTQNTBD-UHFFFAOYSA-N 1-chloro-2-isocyanato-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(Cl)=C1N=C=O OCBLPDGFTQNTBD-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- NMFFUUFPJJOWHK-UHFFFAOYSA-N 2-phenoxyaniline Chemical compound NC1=CC=CC=C1OC1=CC=CC=C1 NMFFUUFPJJOWHK-UHFFFAOYSA-N 0.000 description 1
- MELYYJJKRWTTNN-UHFFFAOYSA-N 2-quinazolin-2-ylguanidine Chemical compound C1=CC=CC2=NC(NC(=N)N)=NC=C21 MELYYJJKRWTTNN-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- QEIQEORTEYHSJH-UHFFFAOYSA-N Armin Natural products C1=CC(=O)OC2=C(O)C(OCC(CCO)C)=CC=C21 QEIQEORTEYHSJH-UHFFFAOYSA-N 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000003417 Central Sleep Apnea Diseases 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 101710172108 Na(+)/H(+) antiporter NhaC Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 108091006647 SLC9A1 Proteins 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- NTECHUXHORNEGZ-UHFFFAOYSA-N acetyloxymethyl 3',6'-bis(acetyloxymethoxy)-2',7'-bis[3-(acetyloxymethoxy)-3-oxopropyl]-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylate Chemical compound O1C(=O)C2=CC(C(=O)OCOC(C)=O)=CC=C2C21C1=CC(CCC(=O)OCOC(C)=O)=C(OCOC(C)=O)C=C1OC1=C2C=C(CCC(=O)OCOC(=O)C)C(OCOC(C)=O)=C1 NTECHUXHORNEGZ-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- JEPPYVOSGKWVSJ-UHFFFAOYSA-N bicyclo[2.2.1]heptan-3-amine Chemical compound C1CC2C(N)CC1C2 JEPPYVOSGKWVSJ-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000012105 intracellular pH reduction Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229950001248 squalamine Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
IN THE MATTER OF an Australian Application corresponding to PCT Application PCT/EPO2/13921 I, Dethard LAMPE Dipl.-Chem., PhD, CChem, MRSC, translator to RWS Group plc, of Europa House, Marsham Way, Gerrards Cross, Buckinghamshire, England, do solemnly and sincerely declare that I am conversant with the English and German languages and am a competent translator thereof, and that to the best of my knowledge and belief the following is a true and correct translation of the PCT Application filed under No. PCTIEPO2/13921. Date: 30 January 2004 D. L For and on behalf of RWS Group plc (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International publication date (10) International publication number 3 July 2003 (03.07.2003) PCT WO 03/053434 Al (51) International patent classification 7 : A61K 31/4168, HOFMEISTER, Armin; Pfaugasse 16, 55276 31/4184, A61P 11/00, 25/00,33/14,43/00, CO7D 233/50, Oppenheim (DE). WIRTH, Klaus; Robert-Schumann 235/02, 235/30 Ring 104, 65830 Kriftel (DE). 235/02, 235/30 (81) Designated states (national): AE, AG, AL, AM, AT, (21) International application number: PCT/EPO2/13921 AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, (22) International filing date: 9 December 2002 (09.12.2002) KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, (25) Language of filing: German TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,VN, YU, ZA, ZM, ZW. (26) Language of publication: German (84) Designated states (regional): ARIPO-Patent (GH, (30) Data relating to the priority: GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, 101 63 239.8 21 December 2001 (21.12.2001) DE ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, BG, CH, CY, (71) Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, [DE/DE]; Bruningstrasse 50, 65929 Frankfurt (DE). NL, PT, SE, SI, SK, TR) OAPI-Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, (72) Inventors: HEINELT, Uwe; Mosbacher Strasse 54, 65187 TD, TG). Wiesbaden (DE). LANG, Hans-Jochen; RUidesheimer Strasse 7, 65719 Hofheim (DE). Published: - With the International Search Report. [continued on next page] As printed (54) Title: SUBSTITUTED IMIDAZOLIDINES. METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A DRUG OR FOR DIAGNOSIS, AND DRUG CONTAINING SUBSTITrTED IMIDAZOLIDINES (54) Bezeichnung: SUBSTITUIERTE IMIDAZOLIDINE, VERFAHREN ZU IHRER HERSTELLUNG. IHRE VERWENDUNG ALS MEDIKAMENT ODER DIAGNOSTIKUM SOWIE ENTHALTENDES MEDIKAMENT (57) Abstract: The invention relates to new imidazolidine-type R3 compounds of formula (1) in which RI to R7 have the meanings R4 N disclosed in the claims. Said compounds represent potent inhibitors \. R1 ) of sodium/hydrogen exchanger (NHE). particularly NHE. These HN novel compounds are used to produce a drug for the therapy or prophylaxis of the central nervous system, lipometabolism, R5 R7 infestations by ectoparasites, dysfunctions of the gall and for R6 improving respiratory drive. The inventive compounds are R6 therefore used for the therapy of respiratory conditions in the following clinical states and diseases: malfunctioning central respiratory drive (e.g. sleep apnoea, sudden infant death, postoperative hypoxia), muscle-related breathing disturbances, breathing Disturbances following long-term respiration, breathing disturbances when adapting to high mountain areas, obstructive sleep apnoea and a mixed type of sleep apnoea, acute and chronic lung diseases with hypoxia and hypercapnia. Said compounds also increase the muscle tone in the upper respiratory tract so as to suppress snoring. S(57) Zusammenfassung: Die Erfindung betrifft neue Verbindungen vom Typ der Imidazolidine der Formel I, (1) worin RI bis R7 die in den Ansprilchen wiedergegebenen Bedeutungen haben. Sie darstellen potente Inhibitoren des Natrium./Wasserstoff-Austau schers (NHE). insbesondere des NHE. Sie dienen zum Herstellen eines Medikament zur Behandlung oder Prophylaxe des zentralen Nervensystems, des Fettstoffwechsels, des Befalls durch Ektoparasiten, von Stirungen der Gallenfunktion sowie der Verbesserung des Atemantriebes und werden deshalb zur Behandlung von Atmungszustdinden bei folgenden klinischen Zustinden und Krankheiten herangezogen: Gestarter zentraler Atemantrieb (z.B. zentale Schlafapnoen, plOtzlicher Kindstod. postoperative Hypoxie). musku. l .r-bedingte Alemsti6rungen, Atemstrungen nach Langzeitbeatmung. Atemst6rungen bei Adaptation im Hochgebirge, obstruktive und gemischte Form der Schlafapnoen, akute und chmnische Lungenkrankheiten mit Hypoxie und Hyperkapnie. Zusiitzlich erh6hen die Verbindungen den Muskeltonus der oberen Atemwege, so dass das Schnarchen unlerdriickt wird.
WO 03/053434 Al For an explanation of the two-letter codes and the other abbreviations, reference is made to the explanations ("Guidance Notes on Codes and Abbreviations") at the beginning of each regular edition of the PCT Gazette.
WO 03/053434 PCT/EPO2/13921 Description Substituted imidazolidines, method for the production thereof, use thereof as a medicament or a diagnostic tool, and medicament containing substituted 5 imidazolidines The invention relates to substituted imidazolidines of the formula I, R3 R4 N RI1 I HN R5 R7 R2 R6 in which 10 R1 and R2 independently of one another are CN, (C 1
-C
5 )-alkyl, (C2-C5)-alkenyl, (C2-C5) alkynyl, (C 3
-C
6 )-cycloalkyl or (C4-C 6 )-cycloalkenyl where all carbon chains and carbon rings are unsubstituted or, independently of one another, are substituted by 1 - 11 fluorine atoms 15 or by up to two radicals selected from the group consisting of OH,
NH
2 , NHCH 3 , N(CH 3
)
2 and OCH 3 ; or R1 and R2 together with the two carbon atoms to which they are attached are a five- to 20 eight-membered saturated or unsaturated carbon ring, but without any double bond between the two carbon atoms to which R1 and R2 are attached, and where the ring is unsubstituted or substituted by 1 - 12 fluorine atoms 25 or by up to two radicals selected from the group consisting of CH 3 and
OCH
3
;
2 R3 is F, CI, Br, I, (C 1
-C
4 )-alkyl, (C 1
-C
4 )-alkenyl, (C3-C6)-cycloalkyl, OH,
(C
1
-C
4 )-alkoxy, Ophenyl, CN, NO 2 or NH 2 ; where phenyl is unsubstituted or substituted by up to two radicals selected from the group consisting of CH 3 , F, CI, Br, I, OH and OCH 3 ; 5 and where the carbon chains or carbon rings are unsubstituted or substituted by 1 - 11 fluorine atoms; R4 to R6 independently of one another are H, F, CI, Br, I, (C 1
-C
4 )-alkyl, (C 1
-C
4
)
10 alkenyl, (C3-C6)-cycloalkyl, OH, (C 1
-C
4 )-alkoxy, CN, NO 2 , NH 2 , (C 1
-C
4
)
alkylamino or (C 1 -C4)-dialky l amino; where the carbon chains or carbon rings are unsubstituted or substituted by 1 - 11 fluorine atoms; R7 is H, F, Cl, Br, I, (C 1 -C4)-alkyl, (C 1
-C
4 )-alkenyl, (C 3
-C
6 )-cycloalkyl, OH, 15 (C 1
-C
4 )-alkoxy, CN, NO 2 or NH 2 ; where the carbon chains or carbon rings are unsubstituted or substituted by 1 - 11 fluorine atoms; and their pharmaceutically acceptable salts, and the trifluoroacetic acid salts. 20 Preference is given to compounds of the formula I in which R1 and R2 independently of one another are (C 1
-C
5 )-alkyl, (C2-C 5 )-alkenyl, (C 2
-C
5
)
alkynyl, (C 3
-C
6 )-cycloalkyl or (C 4 -C6)-cycloalkenyl, where all carbon chains and carbon rings are unsubstituted or, 25 independently of one another, substituted by 1 - 11 fluorine atoms or by up to two radicals selected from the group consisting of NHCH 3 ,
N(CH
3
)
2 and OCH 3 ; or R1 and R2 30 together with the two carbon atoms to which they are attached are a five- to eight-membered saturated or unsaturated carbon ring, 3 but without any double bond between the two carbon atoms to which R1 and R2 are attached, and where the ring is unsubstituted or substituted by 1 - 12 fluorine atoms 5 or by up to two radicals selected from the group consisting of CH 3 and
OCH
3 ; R3 is F, CI, Br, I, (C 1
-C
4 )-alkyl, (Cl-C4)-alkenyl, (C3-C6)-cycloalkyl, OH,
(C
1
-C
4 )-alkoxy, Ophenyl, CN, NO 2 or NH 2 ; where phenyl is unsubstituted or substituted by up to two radicals 10 selected from the group consisting of CH 3 , F, CI, Br, OH and OCH 3 ; and where the carbon chains or carbon rings are unsubstituted or substituted by 1 - 11 fluorine atoms; R4 to R6 15 independently of one another are H, F, CI, Br, CH 3 , OH, OCH 3 , CN, NO 2 ,
NH
2 , NHCH 3 , N(CH 3
)
2 ; where the methyl groups are unsubstituted or substituted by 1 - 3 fluorine atoms; R7 is H, F, Cl, Br, I, (Cl-C 4 )-alkyl, (C 1
-C
4 )-alkenyl, (C 3
-C
6 )-cycloalkyl, OH, 20 (C 1
-
C 4 )-alkoxy, CN, NO 2 or NH 2 ; where the carbon chains or rings are unsubstituted or substituted by 1 - 11 fluorine atoms; and their pharmaceutically acceptable salts, and the trifluoroacetic acid salts. 25 Very particular preference is given to the following compounds of the formula I: trans-(2-chloro-6-trifluoromethylphenyl)-(octahydrobenzimidazol-2-ylidene)amine hydrochloride, (S,S)-(2,6-dichlorophenyl)-(octahydrobenzimidazol-2-ylidene)amine trifluoroacetic acid salt, 30 cis-(2,6-dichlorophenyl)-(octahydrobenzimidazol-2-ylidene)amine trifluoroacetic acid salt, 4 (R,R)-(2,6-dichlorophenyl)-(octahydrobenzimidazol-2-ylidene)amine trifluoroacetic acid salt, trans-(octahydrobenzimidazol-2-ylidene)-(2-phenoxyphenyl)amine hydrochloride, trans-(2,6-dichlorophenyl)-(4,5-diisopropylimidazolidin-2-ylidene)amine hydrochloride, trans-(2,6-dichlorophenyl)-(4,5-dicyclopropylimidazolidin-2-ylidene)amine trifluoracetic 5 acid salt, cis-(2,6-dichlorophenyl)-(4,5-dicyclopropylimidazolidin-2-ylidene)amine hydrochloride, trans-(2,6-dichlorophenyl)-(4,5-diethylimidazolidin-2-ylidene)amine hydrochloride, (2,6-dichlorophenyl)-(4,5-dimethylimidazolidin-2-ylidene)amine nitric acid salt, trans-(2,6-dichlorophenyl)-(hexahyd rocyclopentaimidazol-2-ylidene)amine 10 trifluoroacetic acid salt. Extraordinary preference is given to the following compounds of the formula I: (S,S)-(2,6-dichlorophenyl)-(octahydrobenzimidazol-2-ylidene)amine trifluoroacetic acid salt, 15 cis-(2,6-dichlorophenyl)-(octahydrobenzimidazol-2-ylidene)amine trifluoroacetic acid salt, (R,R)-(2,6-dichlorophenyl)-(octahydrobenzimidazol-2-ylidene)amine trifluoroacetic acid salt, trans-(2,6-dichlorophenyl)-(4,5-diisopropylimidazolidin-2-ylidene)amine hydrochloride, 20 trans-(2,6-dichlorophenyl)-(4,5-dicyclopropylimidazolidin-2-ylidene)amine trifluoroacetic acid salt, cis-(2,6-dichlorophenyl)-(4,5-dicyclopropylimidazolidin-2-ylidene)amine hydrochloride, trans-(2,6-dichlorophenyl)-(4,5-diethylimidazolidin-2-ylidene)amine hydrochloride, (2,6-dichlorophenyl)-(4,5-dimethylimidazolidin-2-ylidene)amine nitric acid salt,trans-(2,6-dichlorophenyl)-(hexahydrocyclopentaimidazol-2-ylidene)amine 25 trifluoroacetic acid salt. Suitable acid addition salts are salts of all pharmacologically acceptable acids, for example halides, in particular hydrochlorides, lactates, sulfates, citrates, tartrates, acetates, phosphates, methylsulfonates, p-toluenesulfonates, adipinates, fumarates, 30 gluconates, glutamates, glycerolphosphates, maleates and pamoates. This group also corresponds to the physiologically acceptable anions; but also trifluoroacetates.
5 If the compounds of the formula I contain one or more centers of asymmetry, the compounds can be both S- and R-configured. The compounds can be present as optical isomers, as diastereomers, as racemates or as mixtures thereof. 5 The compounds of the formula I can furthermore be present as tautomers or as a mixture of tautomeric structures. This refers in particular to the following tautomers: R3 H R3 H R3 H H R3 H I R4 N ~N R4 Nzz N R4 N N R1 R1 RI HN R5 R7 R5 R5 R7 R2 R2 R2 R6 R6 R6 10 If R1 and R2 are different and if the nitrogen-carbon double bond has sufficient configurational stability, it is also possible for two double-bond isomers to exist: R3 H R3 H / / R4 Nz N R4 N N RI R2 HN HN R5 # R7 R5 R7 R1 R6 R6 15 The carbon radicals mentioned, or the partially or fully fluorinated or substituted carbon radicals, can be straight-chain or branched. Also described are methods for preparing the compounds used. Thus, the substances described by formula I can be prepared in a manner known to 20 the person skilled in the art from the isothiocyanate II parent compounds and the appropriate diamines Ill.
6 R4 R5 R3 H2N R1 III R6 NCS R7 H 2 N R2 The thiourea derivative which is formed as an intermediate is cyclized using methyl iodide (Synthesis, 1974, 41 - 42) or carbodiimide (Synthesis, 1977, 864 - 865) to give 5 the corresponding imidazolidine I. If the isothiocyanates II employed here are not commercially available, they can be prepared in a manner known from the literature from the corresponding anilines, using methods known to the person skilled in the art, for example by treatment with thiophosgene (J. Med. Chem., 1975, 18, 90-99) or thiocarbonyl diimidazole (Justus Liebigs Ann. Chem., 1962, 657, 104). 10 In addition to the isothiocyanates II described above, it is also possible to successfully react the isocyanates IV with amines of the type of formula III to give compounds of the formula I. Here, the urea derivative which is formed as an intermediate is cyclized using phosphorus oxychloride to give the corresponding imidazolidines of the formula 15 I. R4 R5 R3 R6 "NCO R7 IV In the present invention, it was surprisingly possible to demonstrate that the 20 compounds described are potent inhibitors of the sodium/hydrogen exchanger (NHE), in particular of NHE3. The NHE3 inhibitors known to date are derived from compounds of the acylguanidine type (EP-A 825 178, HOE 96/F226), of the norbornylamine type (DE 199 60 204.2- 7 HMR 99 / L 073), of the 2-guanidinoquinazoline type (WO 01 79 186 Al or of the benzamidine type (WO 01 21582 A1, WO 01 72 742 Al ). Squalamine, which has also been described as NHE3 inhibitor (M. Donowitz et al. Am. J. Physiol. 276 (Cell Physiol. 45): C136 - C144) is, unlike the compounds of the formula I, not effective immediately 5 but reaches its maximum potency only after one hour. Clonidine, which is similar to the compounds described here, is known as a weak NHE inhibitor. However, its action on the NHE3 of the rat is, with an IC50 of 620 #M, extremely moderate. In contrast, it shows a certain selectivity for the NHE2, where it 10 has an IC50 of 42 pM (J. Orlowski et al J. Biol. Chem. 268, 25536). It would therefore be more accurate to refer to clonidine as an NHE2 inhibitor. In addition to the weak NHE action, clonidine has a high affinity for the adrenergic alpha2 receptor and the imidazoline 11 receptor, mediating a strong hypotensive action (Ernsberger et al Eur. J. Pharmacol. 134, 1, 1987). 15 Compounds of the formula I have increased NHE3 activity and reduced 11 and alpha2 activity. NHE3 is found in the body of various species, preferably in the gall bladder, the intestine and the kidney (Larry Fliegel et al, Biochem. Cell. Biol. 76: 735 - 741, 1998), 20 but can also be detected in the brain (E. Ma et al. Neuroscience 79: 591 - 603). Owing to this unexpected property, the compounds of formula I are suitable for treating disorders caused by oxygen deficiency. As a result of their pharmacological properties, the compounds are highly suitable for use as antiarrhythmics having a cardioprotective 25 component, for infarct prophylaxis and infarct treatment and for treatment of angina pectoris, and they also inhibit, or strongly reduce, in a preventative manner, the pathophysiological processes which contribute to ischemically induced damage, in particular those which trigger ischemically induced cardiac arrhythmias. Owing to their protective action against pathological hypoxic and ischemic situations, the compounds 30 of the formula I according to the invention can, as inhibitors of the cellular Na+/H + exchange mechanisms, be used as medicaments for treating all acute or chronic damage caused by ischemia, or diseases induced primarily or secondarily by this 8 damage. This relates to their use as medicaments for surgical interventions, for example organ transplantations, where the compounds can be used both for protecting the organs in the donor before and during removal, for protecting organs that have been removed, for example by treatment with or storage in physiological bath fluids, 5 and also during transfer into the recipient organism. The compounds are also useful medicaments with protective action during angioplastic surgical interventions, for example at the heart, but also in peripheral vessels. Owing to their protective action against ischemically induced damage, the compounds are also suitable for use as medicaments for treating ischemias of the nervous system, in particular of the CNS, 10 where they can be used, for example, for treating stroke or cerebral edema. Moreover, the compounds of the formula I to be used according to the invention are also suitable for treating forms of shock, such as, for example, of allergic, cardiogenic, hypovolemic and bacterial shock. 15 Furthermore, the compounds induce an improvement in the respiratory drive and are therefore used for the treatment of respiratory conditions in the following clinical conditions and diseases: disturbed central respiratory drive (e.g. central sleep apnea, sudden infant death, post operative hypoxia), muscular-related respiratory disorders, respiratory disorders after long-term ventilation, respiratory disorders during adaptation 20 in a high mountain area, obstructive and mixed forms of sleep apnea, acute and chronic lung diseases with hypoxia and hypercapnia. The compounds additionally increase the muscle tone of the upper airways, so that snoring is suppressed. 25 A combination of an NHE inhibitor with a carboanhydrase inhibitor (e. g. acetazolamide), the latter producing metabolic acidosis and thereby even increasing the respiratory activity, proves to be advantageous as a result of increased action and decreased use of active compound. 30 It has been shown that the compounds to be used according to the invention have a mild laxative action and accordingly can be used advantageously as laxatives or in the 9 case of threatening intestinal blockage, the prevention of ischemic damage accompanying blockages in the intestinal region being particularly advantageous. It is furthermore possible to prevent gallstone formation. 5 Moreover, the compounds of the formula I to be used according to the invention can exert a strong inhibitory action on the proliferation of cells, for example fibroblast cell proliferation and the proliferation of the smooth vascular muscle cells. The compounds of the formula I are therefore suitable as valuable therapeutics for diseases in which 10 cell proliferation is a primary or secondary cause, and can therefore be used as antiatherosclerotics, agents against diabetic late complications, cancers, fibrotic disorders such as pulmonary fibrosis, liver fibrosis or kidney fibrosis, organ hypertrophy and hyperplasia, in particular in prostate hyperplasia or prostate hypertrophy. 15 The compounds according to the invention are effective inhibitors of the cellular sodium/proton antiporter (Na/H exchanger) which is raised in numerous disorders (essential hypertension, atherosclerosis, diabetes etc.) even in those cells which are easily accessible to measurement, such as, for example, in erythrocytes, platelets or 20 leukocytes. The compounds to be used according to the invention are therefore suitable as outstanding and simple scientific tools, for example in their use as diagnostics for the determination and differentiation of certain forms of hypertension, but also of atherosclerosis, of diabetes, of proliferative disorders etc. Moreover, the compounds of the formula I are suitable for preventive therapy to prevent the 25 development of high blood pressure, for example of essential hypertension. It has moreover been found that NHE inhibitors exhibit a favorable influence on the serum lipoproteins. It is generally recognized that for the formation of artereosclerotic vascular changes, in particular of coronary heart disease, excessively high blood lipid 30 values, 'hyperlipoproteinemias', are an essential risk factor. The lowering of increased serum lipoproteins is therefore of extreme importance for the prophylaxis and the regression of atherosclerotic changes. The compounds to be used according to the 10 invention can therefore be used for the prophylaxis and regression of atherosclerotic changes by excluding a causal risk factor. With this protection of the vessels against the syndrome of endothelial dysfunction, compounds of the formula I are valuable pharmaceuticals for the prevention and treatment of coronary vascular spasms, of 5 atherogenesis and of atherosclerosis, of left-ventricular hypertrophy and of dilated cardiomyopathy, and thrombotic disorders. The compounds mentioned are therefore advantageously used for the production of a medicament for the prevention and treatment of sleep apneas and muscular-related 10 respiratory disorders; for the production of a medicament for the prevention and treatment of snoring, for the production of a medicament for lowering the blood pressure, for the production of a medicament having laxative action for the prevention and treatment of intestinal blockages; for the production of a medicament for the prevention and treatment of disorders which are induced by ischemia and reperfusion 15 of central and peripheral organs, such as acute kidney failure, stroke, endogenous states of shock, intestinal disorders etc; for the production of a medicament for the treatment of hypercholesterolemia; for the production of a medicament for the prevention of atherogenesis and of atherosclerosis; for the production of a medicament for the prevention and treatment of diseases which are induced by raised cholesterol 20 levels; for the production of a medicament for the prevention and treatment of diseases which are induced by endothelial dysfunction; for the production of a medicament for the treatment of attack by ectoparasites; for the production of a medicament for the treatment of the diseases mentioned in combination with blood pressure-lowering substances, preferably with angiotensin-converting enzyme (ACE) inhibitors and 25 angiotensin receptor antagonists. A combination of an NHE inhibitor of the formula I with an active compound lowering the blood lipid level, preferably with an HMG-CoA reductase inhibitor (e.g. lovastatin or pravastatin), the latter producing a hypolipidemic effect and thereby increasing the hypolipidemic properties of the NHE inhibitor of the formula I, proves to be a favorable combination having intensified action and 30 decreased use of active substance.
11 The administration of sodium/proton exchange inhibitors of the formula I as novel pharmaceuticals for lowering raised blood lipid levels, and the combination of sodium/proton exchange inhibitors with pharmaceuticals having a blood pressure lowering and/or hypolipidemic action is claimed. 5 Pharmaceuticals which contain a compound I can in this case be administered orally, parenterally, intravenously, rectally or by inhalation, the preferred administration being dependent on the particular clinical picture of the disorder. The compounds I can in this case be used on their own or together with pharmaceutical excipients, namely both in 10 veterinary and in human medicine. The person skilled in the art is familiar on the basis of his/her expert knowledge with excipients which are suitable for the desired pharmaceutical formulation. In addition to solvents, gel formers, suppository bases, tablet excipients and other active compound 15 carriers, it is possible to use, for example, antioxidants, dispersants, emulsifiers, antifoams, flavor corrigents, preservatives, solubilizers or colorants. For a form for oral administration, the active compounds are mixed with the additives suitable therefor, such as excipients, stabilizers or inert diluents, and brought by 20 means of the customary methods into the suitable administration forms, such as tablets, coated tablets, hard gelatin capsules, aqueous, alcoholic or oily solutions. Inert carriers which can be used are, for example, gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, in particular cornstarch. In this case, preparation can be carried out either as dry or as moist granules. Possible 25 oily excipients or solvents are, for example, vegetable or animal oils, such as sunflower oil or cod-liver oils. For subcutaneous or intravenous administration, the active compounds used are brought into solution, suspension or emulsion, if desired with the substances 30 customary therefor such as solubilizers, emulsifiers or further excipients. Suitable solvents are, for example: water, physiological saline solution or alcohols, e.g. ethanol, 12 propanol, glycerol, and in addition also sugar solutions such as glucose or mannitol solutions, or alternatively a mixture of the different solvents mentioned. Pharmaceutical formulations suitable for administration in the form of aerosols or 5 sprays are, for example, solutions, suspensions or emulsions of the active compound of the formula I in a pharmaceutically innocuous solvent, such as, in particular, ethanol or water, or a mixture of such solvents. If required, the formulation can also contain still other pharmaceutical excipients such 10 as. surfactants, emulsifiers and stabilizers, and a propellant. Such a preparation customarily contains the active compound in a concentration of approximately 0.1 to 10, in particular of approximately 0.3 to 3, % by weight. The dose of the active compound of the formula I to be administered and the 15 frequency of administration depend on the potency and duration of action of the compounds used; moreover also on the nature and severity of the disease to be treated and on the sex, age, weight and individual responsiveness of the mammal to be treated. 20 On average, the daily dose of a compound of the formula I in the case of a patient weighing approximately 75 kg is at least 0.001 mg/kg, preferably 0.1 mg/kg, to at most 30 mg/kg, preferably 1 mg/kg, of bodyweight. In acute episodes of the diseases, for instance, directly after a myocardial infarct, even higher and especially more frequent doses may also be necessary, e.g. up to 4 individual doses per day. In particular in the 25 case of i.v. administration, for example in the case of an infarct patient in the intensive care unit, up to 200 mg/kg per day may be necessary. Descriptions of the experiments and examples: 30 List of abbreviations used: Rt retention time 13 TFA trifluoroacetic acid LCMS liquid chromatography mass spectroscopy MS mass spectroscopy
CI
+ chemical ionization, positive mode 5 ES + electrospray, positive mode General: The retention times (Rt) stated below are based on LCMS measurements with the 10 following parameters: Method A: Stationary phase: Merck Purospher 3p 2 x 55 mm Mobile phase: 95% H 2 0 (0.05% TFA)- 95% acetonitrile; 4 min; 95% acetonitrile; 1.5 min -+ 5% acetonitrile; 1 min; 0.5 ml/min. 15 Method B: Stationary phase: YMC J'sphereODS H80 2 x 33 mm Mobile phase: 95% H 2 0 (0.05% TFA)- 95% acetonitrile; 2.3 min; 95% acetonitrile; 1 min -- 5% acetonitrile; 0.1 min; 1 ml/min. 20 Preparative HPLC was carried out under the following conditions: Stationary phase: Merck Purospher RP18 (10pM) 250 x 25 mm Mobile phase: 90% H 2 0 (0.05% TFA)-+ 90% acetonitrile; 40 min; 25 ml/min 25 If the compounds are enantiomerically pure, the configuration and/or the sign of the optical rotation is given. If these data are missing, the compounds are racemates or not optically active.
14 Example 1: (S,S)-(2,6-Dichlorophenyl)-(octahydrobenzimidazol-2-ylidene)amine trifluoroacetic acid salt Cl HN -HN N TFA CI 2,6-Dichlorophenyl isothiocyanate (600 mg) and (1S,2S)-(+)-1,2-diaminocyclohexane 5 (336 mg) were dissolved in toluene (30 ml) and stirred at 70 0 C for 3 h. The mixture was allowed to stand overnight and the solvent was then removed under reduced pressure, and ether was added to the residue. The resulting thiourea was then filtered off with suction. 840 mg of the desired product were isolated. 10 A fraction of the thiourea obtained in this manner (420 mg) was then admixed with toluene (15 ml) and briefly heated at reflux. N,N'-Dicyclohexylcarbodiimide (226 mg), dissolved in toluene (5 ml), was then added dropwise, and the mixture was stirred at 70 0 C for 5 h. The mixture was allowed to stand overnight and the resulting precipitate was then filtered off and the filtrate was concentrated to dryness. The residue was then 15 purified by preparative HPLC. The pure fractions were combined, the acetonitrile was removed using a rotary evaporator and the aqueous phase was freeze-dried. This gave 70 mg of the desired compound. LCMS-Rt: 3.69 min, (A) MS (ES
+
, M+H+): 284.2 20 Example 2: cis-(2,6-Dichlorophenyl)-(octahydrobenzimidazol-2-ylidene)amine trifluoroacetic acid salt Cl C;: HN- N N H CI TFA 25 15 2,6-Dichlorophenyl isothiocyanate (600 mg) and cis-1,2-diaminocyclohexane (336 mg) were reacted and worked up as described in Example 1. From the 900 mg of thiourea obtained in the first step, 454 mg were reacted further in the next step. This gave 112 mg of the desired compound. 5 LCMS-Rt: 3.65 min, (A) MS (Cl
+
, M+H+): 284.1 Example 3: (R,R)-(2,6-Dichlorophenyl)-(octahydrobenzimidazol-2-ylidene)amine 10 trifluoroacetic acid salt ClHN. N TFA Cl 2,6-Dichlorophenyl isothiocyanate (50 mg) and (R,R)-(-)-1,2-diaminocyclohexane (28 mg) were initially charged in toluene (1.5 ml) and heated at reflux for 15 min. 15 N,N'-Dicyclohexylcarbodiimide (76 mg) was then added, and the mixture was kept further at reflux. The mixture was allowed to stand overnight and the toluene was then removed and the residue was purified by preparative HPLC. Since the first purification gave only contaminated fractions, chromatography was repeated using a different column (MN Nucleosil 100-5-C18 250 x 25 mm; flow rate 20 ml/min), but with 20 otherwise identical conditions. The pure fractions were combined, the acetonitrile was removed using a rotary evaporator and the aqueous phase was freeze-dried. This gave 10 mg of the desired compound. LCMS-Rt: 3.70 min, (A) MS (Cl
+
, M+H+): 284.0 25 16 Example 4: trans-(Octahydrobenzoimidazol-2-ylidene)-(2-phenoxyphenyl)amine hydrochloride CIH N 0 N 5 a) 2-Phenoxyphenyl isothiocyanate 1.96 g (0.011 mol) of thiocarbonyl diimidazole were added to a solution of 1.85 g (0.01 mol) of 2-phenoxyaniline in 50 ml of THF and the mixture was stirred at room temperature for 4 hours, giving, after removal of the solvent by distillation, the compound as a brown amorphous product. 10 b) N-(trans-2-Aminocyclohexyl)-N'-(2-phenoxyphenyl)thiourea A solution of 1.6 g of 2-phenoxyphenyl isothiocyanate in 10 ml of THF was added to a solution of 0.8 g of trans-1,2-diaminocyclohexane in 30 ml of THF, and the mixture was stirred at room temperature for about 4 hours. The solvent was evaporated and the 15 residue was subsequently subjected to column chromatography on silica gel using a mixture of 10 parts of ethyl acetate, 5 parts of n-heptane, 5 parts of methylene chloride, 5 parts of methanol and 1 part of concentrated aqueous ammonia solution, giving the desired compound as an amorphous oily product. 20 c) trans-(Octahydrobenzimidazol-2-ylidene)-(2-phenoxyphenyl)amine hydrochloride 3.4 g of methyl iodide were added to a solution of 1.03 g of N-(trans-2 aminocyclohexyl)-N'-(2-phenoxyphenyl)thiourea in 30 ml of ethanol, and the reaction mixture was kept at reflux for 5 hours. The mixture was allowed to stand overnight and the solvent was then distilled off and the residue was treated with water and 25 subsequently made alkaline using saturated sodium bicarbonate solution. The aqueous phase was extracted with ethyl acetate and the organic extraction phase was evaporated, and the oily residue was then chromatographed on silica gel using a 17 mixture of 10 parts of ethyl acetate, 5 parts of n-heptane, 5 parts of methylene chloride, 5 parts of methanol and 1 part of concentrated aqueous ammonia solution. This gave an oily product which was dissolved in ethyl acetate and acidified using a saturated solution of HCI gas in diethyl ether. The solvent was distilled off and the 5 residue was then dissolved in water and subjected to freeze-drying. This gave 0.49 g of a solid of m.p. 1100C. MS (ES
+
, M+H+): 308.2 10 Example 5: trans-(2-Chloro-6-trifluoromethylphenyl)-(octahydrobenzimidazol-2 ylidene)amine hydrochloride F F N F ClH CIl 15 a) N-(trans-2-Aminocyclohexyl)-N'-(2-chloro-6-trifluoromethylphenyl)urea A solution of 0.46 g of trans-1,2-diaminocyclohexane in 10 ml of THF was added to a solution of 1.6 g of 2-chloro-6-trifluoromethylphenyl isocyanate in 30 ml of THF, and the mixture was stirred at room temperature for about 3 hours. The mixture was allowed to stand overnight and the solvent was then distilled off, giving 0.57 g of the 20 desired compound as a semi-solid yellow product. b) trans-(2-Chloro-6-trifluoromethylphenyl)-(octahydrobenzimidazol-2-ylidene)amine hydrochloride 0.57 g of N-(trans-2-aminocyclohexyl)-N'-(2-chloro-6-trifluoromethylphenyl)urea in 25 20 ml of phosphorus oxychloride (POCl 3 ) was boiled at reflux for 4-5 hours. The POCl 3 was distilled off, water was added to the residue and the pH was adjusted to 7 8 using 2N NaOH. The mixture was then extracted with ethyl acetate, the organic solvent was distilled off and the residue was chromatographed on silica gel using a 18 mixture of 20 parts of ethyl acetate, 10 parts of n-heptane and 3 parts of glacial acetic acid. After removal of the eluent by distillation, the white solid residue was dissolved in a little ethyl acetate and acidified using a saturated solution of HCI gas in diethyl ether. Removal of the solvent by distillation and treatment of the residue with diisopropyl 5 ether gave 0.4 g of the desired product as a solid of m.p. 160 - 1650C. MS (ClI
+
, M+H+): 318.3 Example 6: trans-(4,5-Di-tert-butylimidazolidin-2-ylidene)-(2,6-dichlorophenyl)amine 10 hydrochloride Cl I CIH 2,6-Dichlorophenyl isothiocyanate (150 mg) and trans-2,2,5,5-tetramethylhexane-3,4 diamine (127 mg) - analogously to Synthesis 1999, 2, 228; in racemic form - were 15 initially charged in toluene (1.5 ml) and heated at reflux for 15 min. N,N'-Dicyclohexylcarbodiimide (126 mg), dissolved in 2 ml of toluene, was then added, and the mixture was kept at reflux. After standing overnight, the toluene was removed under reduced pressure and the residue was purified by preparative HPLC. The pure fractions were combined, the acetonitrile was removed using a rotary evaporator and 20 the aqueous phase was neutralized with saturated potassium carbonate solution and extracted three times with ethyl acetate. The combined ethyl acetate phases were washed with saturated sodium chloride solution and then dried over magnesium sulfate. The drying agent was filtered off, the mixture was concentrated and the residue was then taken up in water, 2N hydrochloric acid was added and the mixture 25 was freeze-dried. This gave 111 mg of the desired compound. LCMS-Rt: 4.43 min, (A) MS (Cl
+
, M+H ): 342.2 19 Example 7: trans-(2,6-Dichlorophenyl)-(4,5-diisopropylimidazolidin-2-ylidene)amine hydrochloride CI Cl CIH 5 trans-2,5-Dimethylhexane-3,4-diamine (226 mg) - analogously to Synthesis 1999, 2, 228; in racemic form - was initially charged in THF (2.5 ml), and 2,6-dichlorophenyl isothiocyanate was added a little at a time (portions of 150, 80 and 40 mg) at room temperature. N,N'-Dicyclohexylcarbodiimide (324 mg) was then added, and the mixture was further stirred at room temperature. To complete the reaction, some more 10 N,N'-dicyclohexylcarbodiimide was added. The mixture was allowed to stand overnight, and the resulting precipitate was then filtered off with suction and the filtrate was concentrated. The residue was purified by preparative HPLC. The pure fractions were combined, the acetonitrile was removed using a rotary evaporator and the aqueous phase was neutralized with saturated potassium carbonate solution and 15 extracted three times with ethyl acetate. The combined ethyl acetate phases were washed with saturated sodium chloride solution and then dried over magnesium sulfate. The drying agent was filtered off and the mixture was concentrated, and the residue was then taken up in water, 2N hydrochloric acid was added and the mixture was freeze-dried. This gave 220 mg of the desired compound. 20 LCMS-Rt: 1.93 min, (B) MS (ES
+
, M+H+): 314.1 The compounds described in the table below were synthesized according to the 25 examples stated in each case: 20 Analo Ex- Salt gously MS LCMS Salt ample to Ex- [M+H ] Rt [min] ample CN 309.0 8 TFA 7 39 1.84 (B) N (ES+) CI 9 "" < ... HCl 7 309.1 (ES) 1.87 (B) CI Cl ¢; " lH N " 286.1 10N ...... HCI 7 3091 (ES+) 1.75 (B) H ci ci 10 HN . ... HI 7286.1 17 B C N 7 11, ,,N-<N :3 TFA 7 270.1 (ES ) 1.56 (B) , CI H 11 12
HNO
3 CI Pharmacological data: 5 Test description: 21 In this test, the recovery of the intracellular pH (pHi) after an acidification, which starts when the NHE is capable of functioning, even under bicarbonate-free conditions, was determined. For this purpose, the pH was determined using the pH-sensitive fluorescent dye BCECF (calbiochem, the precursor BCECF-AM is employed). The 5 cells were initially loaded with BCECF. The BCECF fluorescence was determined in a "ratio fluorescence spectrometer" (Photon Technology International, South Brunswick, N.J., USA) with excitation wavelengths of 505 and 440 nm and an emission wavelength of 535 nm, and was converted into the pH i using calibration plots. The cells were incubated in NH 4 CI buffer (pH 7.4) (NH 4 CI buffer: 115 mM NaCI, 20 mM 10 NH 4 CI, 5 mM KCI, 1 mM CaCl 2 , 1 mM MgSO 4 , 20 mM Hepes, 5 mM glucose, 1 mg/ml BSA; a pH of 7.4 is established with 1 M NaOH) even during the BCECF loading. The intracellular acidification was induced by addition of 975 pl of an NH4CI-free buffer (see below) to 25 /1 aliquots of the cells incubated in NH 4 CI buffer. The subsequent rate of pH recovery was recorded in the case of NHE1 for two minutes, in the case of 15 NHE2 for five minutes and in the case of NHE3 for three minutes. To calculate the inhibitory power of the tested substances, the cells were initially investigated in buffers in which complete or absolutely no pH recovery took place. For complete pH recovery (100%), the cells were incubated in Na+-containing buffer (133.8 mM NaCI, 4.7 mM KCI, 1.25 mM CaCI2, 1.25 mM MgCl 2 , 0.97 mM Na 2
HPO
4 , 0.23 mM NaH 2
PO
4 , 5 mM 20 Hepes, 5 mM glucose, a pH of 7.0 is established with 1 M NaOH). To determine the 0% value, the cells were incubated in an Na+-free buffer (133.8 mM choline chloride, 4.7 mM KCI, 1.25 mM CaCl2, 1.25 mM MgCI 2 , 0.97 mM K 2
HPO
4 , 0.23 mM KH 2
PO
4 , 5 mM Hepes, 5 mM glucose, a pH of 7.0 is established with 1 M KOH). The substances to be tested were made up in the Na+-containing buffer. Recovery of the 25 intracellular pH at the tested concentration of a substance was expressed as a percentage of the maximum recovery. Using the Sigma-Plot program, the IC value of the substance in question was calculated for the individual NHE subtypes using the percentages for pH recovery.
22 Results: IC50 [pM], Example (rNHE3) 5 19 7 1.1 12 -3
Claims (19)
1. An imidazolidine of the formula R3 R4 NzRI .Co -R1I HN R5 R7 R2 R6 in which 5 R1 and R2 independently of one another are CN, (C 1 -C 5 )-alkyl, (C2-C5)-alkenyl, (C
2 -C 5 ) alkynyl, (C3-C 6 )-cycloalkyl or (C4-C6)-cycloalkenyl where all carbon chains and carbon rings are unsubstituted or, independently of one another, are substituted by 1 - 11 fluorine atoms 10 or by up to two radicals selected from the group consisting of OH, NH 2 , NHCH 3 , N(CH 3 ) 2 and OCH 3 ; or R1 and R2 together with the two carbon atoms to which they are attached are a five- to 15 eight-membered saturated or unsaturated carbon ring, but without any double bond between the two carbon atoms to which R1 and R2 are attached, and where the ring is unsubstituted or substituted by 1 - 12 fluorine atoms 20 or by up to two radicals selected from the group consisting of CH 3 and OCH 3 ; R3 is F, CI, Br, I, (C 1 -C 4 )-alkyl, (C 1 -C4)-alkenyl, (C3-C6)-cycloalkyl, OH, (C 1 -C4)-alkoxy, Ophenyl, CN, NO 2 or NH 2 ; where phenyl is unsubstituted or substituted by up to two radicals 25 selected from the group consisting of CH 3 , F, CI, Br, I, OH and OCH 3 ; and 24 where the carbon chains or carbon rings are unsubstituted or substituted by 1 - 11 fluorine atoms; R4 to R6 independently of one another are H, F, Cl, Br, I, (C 1 -C4)-alkyl, (C1-C4) 5 alkenyl, (C3-C6)-cycloalkyl, OH, (Cl-C4)-alkoxy, CN, NO 2 , NH 2 , (Cl-C4) alkylamino or (C 1 -C4)-dialkylamino; where the carbon chains or carbon rings are unsubstituted or substituted by I - 11 fluorine atoms; R7 is H, F, CI, Br, I, (C 1 -C 4 )-alkyl, (Cl-C4)-alkenyl, (C3-C6)-cycloalkyl, OH, 10 (Cl-C4)-alkoxy, CN, NO 2 or NH 2 ; where the carbon chains or carbon rings are unsubstituted or substituted by 1 - 11 fluorine atoms; and its pharmaceutically acceptable salts, and the trifluoroacetic acid salts. 15 2. A compound of the formula I as claimed in claim 1 in which R1 and R2 independently of one another are (C 1 -C 5 )-alkyl, (C 2 -C 5 )-alkenyl, (C 2 -C 5 ) alkynyl, (C 3 -C 6 )-cycloalkyl or (C 4 -C 6 )-cycloalkenyl, where all carbon chains and carbon rings are unsubstituted or, 20 independently of one another, substituted by 1 - 11 fluorine atoms or by up to two radicals selected from the group consisting of NHCH 3 , N(CH 3 ) 2 and OCH 3 ; or R1 and R2 25 together with the two carbon atoms to which they are attached are a five- to eight-membered saturated or unsaturated carbon ring, but without any double bond between the two carbon atoms to which R1 and R2 are attached, and 25 where the ring is unsubstituted or substituted by 1 - 12 fluorine atoms or by up to two radicals selected from the group consisting of CH 3 and OCH 3 ; R3 is F, CI, Br, I, (C1 -C4)-alkyl, (Cl-C4)-alkenyl, (C 3 -C6)-cycloalkyl, OH, 5 (C 1 -C 4 )-alkoxy, Ophenyl, CN, NO 2 or NH 2 ; where phenyl is unsubstituted or substituted by up to two radicals selected from the group consisting of CH 3 , F, CI, Br, OH and OCH 3 ; and where the carbon chains or carbon rings are unsubstituted or 10 substituted by 1 - 11 fluorine atoms; R4 to R6 independently of one another are H, F, CI, Br, CH 3 , OH, OCH 3 , CN, NO 2 , NH 2 , NHCH 3 , N(CH 3 ) 2 ; where the methyl groups are unsubstituted or substituted by 1 - 3 15 fluorine atoms; R7 is H, F, Cl, Br, I, (Cl-C4)-alkyl, (Cl-C 4 )-alkenyl, (C 3 -C 6 )-cycloalkyl, OH, (C 1 -C4)-alkoxy, CN, NO 2 or NH 2 ; where the carbon chains or rings are unsubstituted or substituted by 1 - 11 fluorine atoms; 20 and its pharmaceutically acceptable salts, and the trifluoroacetic acid salts.
3. A compound of the formula I as claimed in claim 1 or 2 selected from the group consisting of: trans-(2-chloro-6-trifluoromethylphenyl)-(octahyd robenzimidazol-2-ylidene)amine 25 hydrochloride, (S,S)-(2,6-dichlorophenyl)-(octahydrobenzimidazol-2-ylidene)amine trifluoroacetic acid salt, cis-(2,6-dichlorophenyl)-(octahydrobenzimidazol-2-ylidene)amine trifluoroacetic acid salt, 30 (R,R)-(2,6-dichlorophenyl)-(octahydrobenzimidazol-2-ylidene)amine trifluoroacetic acid salt, 26 trans-(octahydrobenzimidazol-2-ylidene)-(2-phenoxyphenyl)amine hydrochloride, trans-(2,6-dichlorophenyl)-(4,5-diisopropylimidazolidin-2-ylidene)amine hydrochloride, trans-(2,6-dichlorophenyl)-(4,5-dicyclopropylimidazolidin-2-ylidene)amine trifluoracetic acid salt, 5 cis-(2,6-dichlorophenyl)-(4,5-dicyclopropylimidazolidin-2-ylidene)amine hydrochloride, trans-(2,6-dichlorophenyl)-(4,5-diethylimidazolidin-2-ylidene)amine hydrochloride, (2,6-dichlorophenyl)-(4,5-dimethylimidazolidin-2-ylidene)amine nitric acid salt, trans-(2,6-dichlorophenyl)-(hexahydrocyclopentaimidazol-2-ylidene)amine trifluoroacetic acid salt. 10
4. A compound of the formula I as claimed in one or more of claims 1 to 3, selected from the group consisting of: (S,S)-(2,6-dichlorophenyl)-(octahydrobenzimidazol-2-ylidene)amine trifluoroacetic acid salt, 15 cis-(2,6-dichlorophenyl)-(octahydrobenzimidazol-2-ylidene)amine trifluoroacetic acid salt, (R,R)-(2,6-dichlorophenyl)-(octahydrobenzimidazol-2-ylidene)amine trifluoroacetic acid salt, trans-(2,6-dichlorophenyl)-(4,5-diisopropylimidazolidin-2-ylidene)amine hydrochloride, 20 trans-(2,6-dichlorophenyl)-(4,5-dicyclopropylimidazolidin-2-ylidene)amine trifluoroacetic acid salt, cis-(2,6-dichlorophenyl)-(4,5-dicyclopropylimidazolidin-2-ylidene)amine hydrochloride, trans-(2,6-dichlorophenyl)-(4,5-diethylimidazolidin-2-ylidene)amine hydrochloride, (2,6-dichlorophenyl)-(4,5-dimethylimidazolidin-2-ylidene)amine nitric acid salt, 25 trans-(2,6-dichlorophenyl)-(hexahydrocyclopentaimidazol-2-ylidene)amine trifluoroacetic acid salt.
5. The use of a compound I as claimed in claim 1 for preparing a medicament for the treatment or prophylaxis of disorders of the respiratory drive. 30 27
6. The use of a compound I as claimed in claim 1 for preparing a medicament for the treatment or prophylaxis of respiratory disorders, in particular respiratory disorders associated with sleeping, such as sleep apnea. 5
7. The use of a compound I as claimed in claim 1 for preparing a medicament for the treatment or prophylaxis of snoring.
8. The use of a compound I as claimed in claim 1 for preparing a medicament for the treatment or prophylaxis of acute and chronic renal diseases, in particular acute kidney 10 failure and chronic kidney failure.
9. The use of a compound I as claimed in claim 1 for preparing a medicament for the treatment or prophylaxis of disorders of intestinal function. 15
10. The use of a compound I as claimed in claim 1 for preparing a medicament for the treatment or prophylaxis of disorders of gall function.
11. The use of a compound I as claimed in claim 1 for preparing a medicament for the treatment or prophylaxis of ischemic states of the peripheral and central nervous 20 system and of stroke.
12. The use of a compound I as claimed in claim 1 for preparing a medicament for the treatment or prophylaxis of ischemic states of peripheral organs and limbs. 25
13. The use of a compound I as claimed in claim 1 for preparing a medicament for treating states of shock.
14. The use of a compound I as claimed in claim 1 for preparing a medicament for use in surgical operations and organ transplantations. 30
15. The use of a compound I as claimed in claim 1 for preparing a medicament for preserving and storing transplants for surgical interventions. 28
16. The use of a compound I as claimed in claim 1 for preparing a medicament for the treatment of diseases in which cell proliferation is a primary or secondary cause. 5
17. The use of a compound I as claimed in claim 1 for preparing a medicament for the treatment or prophylaxis of disorders of lipid metabolism.
18. The use of a compound I as claimed in claim 1 for preparing a medicament for the treatment or prophylaxis of infection by ectoparasites. 10
19. A medicament, comprising an effective amount of a compound I as claimed in one or more of claims 1 to 3.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10163239.8 | 2001-12-21 | ||
| DE10163239A DE10163239A1 (en) | 2001-12-21 | 2001-12-21 | Substituted imidazolidines, process for their preparation, their use as medicaments or diagnostic agents, and medicaments containing them |
| PCT/EP2002/013921 WO2003053434A1 (en) | 2001-12-21 | 2002-12-09 | Substituted imidazolidines, method for the production thereof, use thereof as a drug or for diagnosis, and drug containing substituted imidazolidines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002361990A1 true AU2002361990A1 (en) | 2003-07-09 |
| AU2002361990B2 AU2002361990B2 (en) | 2008-10-09 |
Family
ID=7710363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002361990A Ceased AU2002361990B2 (en) | 2001-12-21 | 2002-12-09 | Substituted imidazolidines, method for the production thereof, use thereof as a drug or for diagnosis, and drug containing substituted imidazolidines |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1461034B1 (en) |
| JP (1) | JP4571803B2 (en) |
| KR (1) | KR100959031B1 (en) |
| CN (1) | CN100339079C (en) |
| AR (1) | AR037932A1 (en) |
| AT (1) | ATE345797T1 (en) |
| AU (1) | AU2002361990B2 (en) |
| BR (1) | BR0215154A (en) |
| CA (1) | CA2470856A1 (en) |
| CO (1) | CO5590925A2 (en) |
| DE (2) | DE10163239A1 (en) |
| DK (1) | DK1461034T3 (en) |
| ES (1) | ES2275945T3 (en) |
| HR (1) | HRP20040573A2 (en) |
| HU (1) | HUP0600836A2 (en) |
| IL (2) | IL162562A0 (en) |
| MA (1) | MA27149A1 (en) |
| MX (1) | MXPA04005388A (en) |
| MY (1) | MY134344A (en) |
| NO (1) | NO20043009L (en) |
| PE (1) | PE20030741A1 (en) |
| PL (1) | PL368940A1 (en) |
| RS (1) | RS53204A (en) |
| RU (1) | RU2004122415A (en) |
| TW (1) | TW200305408A (en) |
| WO (1) | WO2003053434A1 (en) |
| ZA (1) | ZA200404149B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10323701A1 (en) | 2003-05-22 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Process for the synthesis of heterocyclic compounds |
| US7632970B2 (en) | 2003-06-30 | 2009-12-15 | Sumitomo Chemical Company, Limited | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst |
| DE10341240A1 (en) * | 2003-09-08 | 2005-04-07 | Aventis Pharma Deutschland Gmbh | Substituted thienoimidazoles, process for their preparation, their use as medicament or diagnostic agent, and medicament containing them |
| PL3173408T3 (en) | 2014-07-25 | 2019-05-31 | Taisho Pharma Co Ltd | Heteroaryl substituted phenyl tetrahydroisoquinoline compound |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3236857A (en) * | 1961-10-09 | 1966-02-22 | Boehringer Sohn Ingelheim | 2-(phenyl-amino)-1, 3-diazacyclopentene-(2) substitution products |
| US3202660A (en) * | 1961-10-09 | 1965-08-24 | Boehringer Sohn Ingelheim | Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes |
| EP0070084A3 (en) * | 1981-04-24 | 1983-02-16 | Beecham Group Plc | Imidazoline derivatives |
| DE3712385A1 (en) * | 1987-04-11 | 1988-10-27 | Boehringer Ingelheim Kg | 2-(Phenylimino)imidazolidines |
| GB9313330D0 (en) * | 1993-06-28 | 1993-08-11 | Fujisawa Pharmaceutical Co | New compound and its preparation |
| EP0639573A1 (en) * | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzocondensed five membered heterocycles, process of their preparation, their use as drug, as diagnostic means and pharmaceuticals containing it |
| DE4328869A1 (en) * | 1993-08-27 | 1995-03-02 | Hoechst Ag | Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them |
| KR100257129B1 (en) * | 1993-09-11 | 2000-05-15 | 성재갑 | Novel cephalosphorine antibiotics |
| US5552415A (en) * | 1993-12-21 | 1996-09-03 | Eli Lilly And Company | Method of inhibiting Alzheimer's Disease |
| DE19548812A1 (en) * | 1995-12-27 | 1997-07-03 | Hoechst Ag | Use of inhibitors of the cellular Na · + · / H · + · exchanger (NHE) for the manufacture of a medicament for respiratory stimulation |
| DE19633966A1 (en) * | 1996-08-22 | 1998-02-26 | Hoechst Ag | Phenyl-substituted alkenylcarboxylic acid guanidines, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them |
| DE69816280T2 (en) * | 1997-03-14 | 2004-05-27 | Vertex Pharmaceuticals Inc., Cambridge | INHIBITORS OF THE IMPDH ENZYME |
| DE19945302A1 (en) * | 1999-09-22 | 2001-03-29 | Merck Patent Gmbh | Biphenyl derivatives as NHE-3 inhibitors |
| DE19950898A1 (en) * | 1999-10-22 | 2001-04-26 | Aventis Pharma Gmbh | New heteroaryl substituted fluoroalkyl-benzoylguanidine derivatives useful for treatment of e.g. ischemias, cardiac infarction, angina, shock, atherosclerosis, cancer and metabolic disorders |
| DE19960204A1 (en) * | 1999-12-14 | 2001-06-28 | Aventis Pharma Gmbh | Substituted norlbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostic agents and medicaments containing them |
| DE10015248A1 (en) * | 2000-03-28 | 2001-10-04 | Merck Patent Gmbh | Bisamidino compounds as NHE-3 inhibitors |
| DE10019062A1 (en) * | 2000-04-18 | 2001-10-25 | Merck Patent Gmbh | Use of known and new 2-guanidino-4-aryl-quinazoline derivatives as NHE-3 inhibitors useful for the treatment of e.g. hypertension, thrombosis, cardiac ischemia, peripheral and CNS ischemia |
| DE10060292A1 (en) * | 2000-12-05 | 2002-06-20 | Aventis Pharma Gmbh | Use of substituted benzimidazoles for the manufacture of a medicament for the treatment of diseases which can be influenced by inhibition of the Na + / H + exchanger and medicament containing them |
-
2001
- 2001-12-21 DE DE10163239A patent/DE10163239A1/en not_active Withdrawn
-
2002
- 2002-12-09 PL PL02368940A patent/PL368940A1/en not_active Application Discontinuation
- 2002-12-09 RS YU53204A patent/RS53204A/en unknown
- 2002-12-09 KR KR1020047009820A patent/KR100959031B1/en not_active Expired - Fee Related
- 2002-12-09 CA CA002470856A patent/CA2470856A1/en not_active Abandoned
- 2002-12-09 HU HU0600836A patent/HUP0600836A2/en unknown
- 2002-12-09 JP JP2003554191A patent/JP4571803B2/en not_active Expired - Fee Related
- 2002-12-09 EP EP02796586A patent/EP1461034B1/en not_active Expired - Lifetime
- 2002-12-09 AU AU2002361990A patent/AU2002361990B2/en not_active Ceased
- 2002-12-09 ES ES02796586T patent/ES2275945T3/en not_active Expired - Lifetime
- 2002-12-09 DE DE50208809T patent/DE50208809D1/en not_active Expired - Lifetime
- 2002-12-09 RU RU2004122415/04A patent/RU2004122415A/en not_active Application Discontinuation
- 2002-12-09 IL IL16256202A patent/IL162562A0/en unknown
- 2002-12-09 MX MXPA04005388A patent/MXPA04005388A/en active IP Right Grant
- 2002-12-09 CN CNB028258177A patent/CN100339079C/en not_active Expired - Fee Related
- 2002-12-09 WO PCT/EP2002/013921 patent/WO2003053434A1/en not_active Ceased
- 2002-12-09 HR HR20040573A patent/HRP20040573A2/en not_active Application Discontinuation
- 2002-12-09 BR BR0215154-5A patent/BR0215154A/en not_active IP Right Cessation
- 2002-12-09 DK DK02796586T patent/DK1461034T3/en active
- 2002-12-09 AT AT02796586T patent/ATE345797T1/en not_active IP Right Cessation
- 2002-12-11 PE PE2002001194A patent/PE20030741A1/en not_active Application Discontinuation
- 2002-12-19 AR ARP020105018A patent/AR037932A1/en unknown
- 2002-12-19 TW TW091136596A patent/TW200305408A/en unknown
- 2002-12-20 MY MYPI20024821A patent/MY134344A/en unknown
-
2004
- 2004-05-27 ZA ZA200404149A patent/ZA200404149B/en unknown
- 2004-06-01 MA MA27709A patent/MA27149A1/en unknown
- 2004-06-16 IL IL162562A patent/IL162562A/en not_active IP Right Cessation
- 2004-06-17 CO CO04056920A patent/CO5590925A2/en not_active Application Discontinuation
- 2004-07-15 NO NO20043009A patent/NO20043009L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2275945T3 (en) | 2007-06-16 |
| HUP0600836A2 (en) | 2008-04-28 |
| CA2470856A1 (en) | 2003-07-03 |
| RS53204A (en) | 2006-10-27 |
| EP1461034A1 (en) | 2004-09-29 |
| CN100339079C (en) | 2007-09-26 |
| IL162562A (en) | 2009-12-24 |
| BR0215154A (en) | 2004-10-19 |
| WO2003053434A1 (en) | 2003-07-03 |
| KR20040068322A (en) | 2004-07-30 |
| DE50208809D1 (en) | 2007-01-04 |
| JP2005516947A (en) | 2005-06-09 |
| AU2002361990B2 (en) | 2008-10-09 |
| CO5590925A2 (en) | 2005-12-30 |
| EP1461034B1 (en) | 2006-11-22 |
| TW200305408A (en) | 2003-11-01 |
| MA27149A1 (en) | 2005-01-03 |
| NO20043009L (en) | 2004-07-15 |
| PE20030741A1 (en) | 2003-09-29 |
| PL368940A1 (en) | 2005-04-04 |
| HRP20040573A2 (en) | 2004-10-31 |
| CN1606440A (en) | 2005-04-13 |
| ATE345797T1 (en) | 2006-12-15 |
| MY134344A (en) | 2007-12-31 |
| ZA200404149B (en) | 2006-05-31 |
| JP4571803B2 (en) | 2010-10-27 |
| IL162562A0 (en) | 2005-11-20 |
| AR037932A1 (en) | 2004-12-22 |
| RU2004122415A (en) | 2005-03-27 |
| DE10163239A1 (en) | 2003-07-10 |
| KR100959031B1 (en) | 2010-05-20 |
| DK1461034T3 (en) | 2007-03-26 |
| MXPA04005388A (en) | 2004-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1341770B1 (en) | Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors | |
| US6737423B2 (en) | Substituted heterocyclo-norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | |
| US20080275098A1 (en) | Novel substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic aid | |
| EP0921117B1 (en) | Acylguanidines | |
| EP0748795A2 (en) | Substituted benzyloxycarbonyl guanidines as Na+/H+ exchange inhibitors, process for their preparation, their use as medicinal or diagnostic agents as well as medicament containing them | |
| EP1513834B1 (en) | Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same | |
| AU2002361990B2 (en) | Substituted imidazolidines, method for the production thereof, use thereof as a drug or for diagnosis, and drug containing substituted imidazolidines | |
| US7179829B2 (en) | Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic, and medicament comprising them | |
| MXPA05007247A (en) | N-substituted (benzoimidazole-2-yl) phenyl amines, method for their production, their use as a medicament or diagnostic agent and medicament containing said substances. | |
| DE19950898A1 (en) | New heteroaryl substituted fluoroalkyl-benzoylguanidine derivatives useful for treatment of e.g. ischemias, cardiac infarction, angina, shock, atherosclerosis, cancer and metabolic disorders | |
| DE19542306A1 (en) | Sulfonylamino-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH Free format text: FORMER APPLICANT(S): AVENTIS PHARMA DEUTSCHLAND GMBH |
|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period | ||
| TH | Corrigenda |
Free format text: IN VOL 20, NO 18, PAGE(S) 1742 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN, PATENTSCEASED OR EXPIRED - 2002 DELETE ALL REFERENCE TO 2002361990 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |